Key points are not available for this paper at this time.
Supplemental Table 4: Baseline characteristics in HMA-naïve patients with HR-MDS treated with HMA plus venetoclax versus a contemporary HMA monotherapy cohort.
Bazinet et al. (2024) studied this question.